News

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I ...
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate init ...
General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...
EMED Technologies Director of Clinical Affairs Alex Nikanorov shares the company’s approach to deciding which clinical ...
Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and local biotechnology company Intra-ImmuSG ...
A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based ...
A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...
The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.
TEMPO.CO, Jakarta - A total of 2,095 Indonesians from adolescent to adult age groups have undergone clinical trials for the ...
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...
Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata” or the ...